IL1B and COVID-19: Thus, the local production and release of IL-1β from human vascular cells and monocytes stimulated by the S protein may contribute to vascular dysfunction in the context of COVID-19, favoring vascular inflammation and perhaps amplifying and aggravating pre-existing vascular lesions.